OOIR: Observatory of International Research

Papers

(The TQCC of Lancet Haematology is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?	628
Towards reparatory measures: blood donation, health systems, and men who have sex with men	517
In the trenches	243
Prioritising health equity alongside donation safety – Authors' reply	228
Is there still a role for CNS prophylaxis in diffuse large B-cell lymphoma?	206
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3	152
Illegal blood trade as cause for blood shortages in public hospitals in northern Nigeria	151
Correction to Lancet Haematol 2023; 10: e333–45	151
Zanubrutinib-associated ecchymotic lesions	150
MRD-guided treatment cessation in multiple myeloma	150
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international experts	140
Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and T-cell clones of uncertain significance: are these premalignant conditions sharing a common identity?	128
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenström macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial	112
Optimising communication to patients with venous thromboembolism: development of a provider toolkit	111
Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries	109
Blood cell defence against pathogens	100
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial	100
Correction to Lancet Haematol 2024; 11: e114–26	100
Call to action: equitable comprehensive care for patients with sickle cell disease in the USA	99
Blood deserts: a vision to tackle blood inaccessibility	97
Extensively distributed erythema nodosum in VEXAS syndrome	96
International Society on Thrombosis and Haemostasis Congress 2023	90
Be compliant or compromise?	89
Blinatumomab plus hyper-CVAD: the prelude to a new era in acute lymphocytic leukaemia	87
Production and supply of blood products in Brazil	83

Eltrombopag–cyclosporin A in treating severe aplastic anaemia	82
Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study	81
25 mm Hg versus 35 mm Hg elastic compression stockings to prevent post-thrombotic syndrome after deep vein thrombosis (CELEST): a randomised, double-blind, non-inferiority trial	80
USAID's enduring impact on anaemia management must be preserved	79
Coexisting genetic abnormalities and thrombocytopenia	74
Anaemia in a time of climate crisis	74
Sickle cell disease in India: current status and progress	72
Correction to Lancet Haematol 2023; 10: e433–44	71
Update on SickleInAfrica: a collaborative and multidimensional approach to conduct research and improve health	71
Correction to Lancet Haematol 2025; 12: e294–303	70
Rituximab versus active surveillance in patients with follicular lymphoma	65
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past	62
Variations in antenatal management and outcomes in haemolytic disease of the fetus and newborn: an international, retrospective, observational cohort study	62
Methodological challenges in the development of endpoints for myelofibrosis clinical trials	61
Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: an international, multicentre, retrospective	60
Epidemiology, clinical features, and outcomes of peripheral T-cell lymphoma in Latin America: an international, retrospective, cohort study	60
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, ran	60
[18F]FDG-PET-CT compared with CT for persistent or recurrent neutropenic fever in high-risk patients (PIPPIN): a multicentre, open-label, phase 3, randomised, controlled trial	58
Universal health coverage for children with cancer	58
Oral decitabine plus cedazuridine and venetoclax in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: a single-centre, phase 1/2 study	58
Oreofe Odejide—aiming to raise the bar in haematology care	58
Beyond maximum grade: advancing the measurement and analysis of adverse events in malignant haematology trials in the modern era	57
Could improving mental health disorders help increase cancer survival?	56
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment	55
Correction to Lancet Haematol 2022; Published online July 27. https://doi.org/10.1016/S2352-3026(22)00206-X	54
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial	50
Global effort to evacuate Ukrainian children with cancer and blood disorders who have been affected by war	50
An otherwise smouldering multiple myeloma with a solitary osteolytic lesion and soft-tissue mass	50
Correction to Lancet Haematol 2024; 11: e310–11	49
Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial	47
Haematopoietic cell transplantation for relapsed or refractory classical Hodgkin lymphoma: a retrospective, registry-based cohort study of 19 498 patients from the EBMT Lymphoma Working Group	46
Vacuoles in bone marrow progenitors: VEXAS syndrome and beyond	46
Striking the right balance	44
Secondary haematological malignancies	42
Efficacy or convenience? Subcutaneous blinatumomab as a promising new treatment for B-cell acute lymphoblastic leukaemia	42
Thank you to our 2022 peer reviewers and an update on inclusion and diversity	41
Elotuzumab: no additional effect in patients with newly diagnosed multiple myeloma	41
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation	41
Acute myeloid leukaemia at the extremes	40
Should patients with haemophilia receive gene therapy?	40
Patients first: improving toxicity assessment and reporting	40
2024 ASH Annual Meeting	40
A long-awaited benchmark in lymphomatoid granulomatosis	39
Updated anaemia estimates: implications for global monitoring	39
Haematology and climate change	39
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated VTE – Authors' reply	39
Correction to Lancet Haematol 2024; 11: e521–29	38
Carfilzomib–lenalidomide–dexamethasone versus lenalidomide–dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label,	38
Haemophilia—unparalleled progress but inadequate access	38
Crizanlizumab with or without hydroxyurea in patients with sickle cell disease (STAND): primary analyses from a placebo-controlled, randomised, double-blind, phase 3 trial	38

Sickle cell disease—unity and patient-centred education	38
The challenge of defining the global burden of iron deficiency anaemia	38
Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial	35
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism	34
The Lancet Haematology at 10	33
Gene therapy in China: past, present, and future	33
Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management	33
Leprosy and leukaemia: an unexpected interaction	33
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study	33
Thank you to The Lancet Haematology's peer reviewers in 2022	32
Integrated molecular and immunological features of human T-lymphotropic virus type 1 infection and disease progression to adult T-cell leukaemia or lymphoma	31
Bexmarilimab plus azacitidine for high-risk myelodysplastic syndrome and relapsed or refractory acute myeloid leukaemia: results from the dose-escalation part of a multicentre, single-arm, phase 1/2 t	31
Life beyond blood disorders	31
Management of pregnancies with anti-K alloantibodies and the predictive value of anti-K titration testing	31
The impact of patient ethnicity on haematopoietic cell transplantation outcome: a retrospective cohort study on the UK experience	31
Can defibrotide prophylaxis prevent sinusoidal obstruction syndrome following haematopoietic stem-cell transplantation?	31
Sovleplenib in immune thrombocytopenia	31
Breaking sex biases: access for all in haemophilia care	31
Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7)	30
Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow	30
Beyond maximum grade: introduction to The Lancet Haematology Adverse Events Reporting Series	30
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study	30
Anti-BCMA/GPRC5D bispecific CAR T cells for relapsed or refractory multiple myeloma: is 1 + 1 greater than 2?	30
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial	29
Menstruation in Nepal: tradition, stigma, and transition	29
Don Thomas: leading the charge to bone marrow transplantation	28
Acquired haemophilia in an Edo period Japanese surgical casebook	28
Needles were the least of my worries	28
A treatise on clinical trials	27
From diagnosis to equitable care in bleeding disorders	26
Preventive interventions for vasovagal reactions in whole blood donors: a cluster-randomised, stepped-wedge, crossover trial of 73 sites involving 1·4 million donors in England	26
Patients receiving allogeneic haematopoietic stem-cell transplantation and clinical outcomes after early access to palliative care	26
Monumen-TAL progress in the treatment of relapsed multiple myeloma	25
Experience of the Anaemia Mukt Bharat anaemia control programme in India	24
The effects of upward revision of haemoglobin thresholds for anaemia in blood donations	24
Heavy menstrual blood loss in patients with von Willebrand disease: an unsolved problem	23
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM	23
Virtual twins for personalised CAR T-cell therapy in myeloma	23
Mental health disorders and survival among older patients with diffuse large B-cell lymphoma in the USA: a population-based study	23
Ask, do not tell: consulting a patient advisory board to understand unmet needs of patients with GVHD in Europe	23
Living with a bleeding disorder as a woman	22
Lines of the haematology community	22
Riociguat in patients with sickle cell disease and hypertension or proteinuria (STERIO-SCD): a randomised, double-blind, placebo controlled, phase 1–2 trial	22
Clinical trial design change implementation for inclusive studies	22
Intravenous iron for non-anaemic iron deficiency in pregnancy: a multicentre, two-arm, randomised controlled trial	22
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation t	22
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study	22
Antifibrinolytics do not add to the benefits of platelet transfusion	21
The effects of revised haemoglobin cutoffs on the global burden of anaemia	21
Correction to Lancet Haematol 2025; 12: e562–63	21
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia	20
Mitapivat for treatment of pyruvate kinase deficiency	20
2025 ASH Annual Meeting	20
Immunochemotherapy for life-threatening haematological malignancies in pregnancy: a systematic review of the literature and cross-sectional analysis of clinical trial eligibility	20
Making blood count	20
Short versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial	20
Reducing toxic waste: improving toxicity capture in childhood cancer	20
Sickle cell disease: a neglected health priority	20
Oleksandr Lysytsia: the war in Ukraine has changed everything about our lives	20
Oral decitabine and cedazuridine maintenance after haematopoietic stem-cell transplantation in very high-risk acute myeloid leukaemia or myelodysplastic syndrome (GFM-DACORAL-DLI): a multicentre, sing	19
Improved survival and enhanced quality of life through anaemia correction in lower risk myelodysplastic syndromes: meaningful insights from an EUMDS Registry study	19
COVID-19 vaccination antibody responses in patients with aplastic anaemia and paroxysmal nocturnal haemoglobinuria	19
Regional empowerment through decentralised governance under a centralised regulatory system facilitates the development of cellular therapy in China	19
Implications of changes in WHO haemoglobin elevation adjustment guidelines on global, regional, and national anaemia burden, 1990–2023: a population-based modelling study	18
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose e	18
Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): phase 2 results from an open-label, single arm, multicentre phase 1/2 trial	18
Efficacy and safety of sovleplenib (HMPL-523) in adult patients with chronic primary immune thrombocytopenia in China (ESLIM-01): a randomised, double-blind, placebo-controlled, phase 3 study	18
Incidence and prognosis of superficial vein thrombosis during pregnancy and the post-partum period: a Danish nationwide cohort study	18
Reactivating hope for TP53-mutated acute myeloid leukaemia?	17
Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trial	17
Time to define and refine maintenance strategies in acute myeloid leukaemia	17
Epistemic limitations of measurable residual disease in haematological malignancies	17
Ebola outbreak: why haematology matters	17
Lallindra Gooneratne—maintaining treatment flow amid crisis	17
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial	17
Protein-losing enteropathy in marginal zone lymphoma: tissue is the issue	17
New hope, old challenges in myelodysplastic syndromes	16
Correction to Lancet Haematol 2023; 10: e203–12	16
Iron deficiency anaemia—an ongoing challenge	16
From enrolment to authorship: racial and global disparities in phase 3 multiple myeloma clinical trials	16

Sexually transmitted infections in the context of haematological malignancies	16
Correction to Lancet Haematol 2024; 11: e862–72	16
Pembrolizumab and low-dose, single-fraction radiotherapy for patients with relapsed or refractory multiple myeloma: a prospective, single-centre, single-group, open-label, phase 2 pilot trial in the U	15
Conditioning regimens for HSCT for patients with high-risk myelodysplastic syndrome and secondary acute myeloid leukaemia	15
Haemoglobin thresholds to define anaemia from age 6 months to 65 years: estimates from international data sources	15
Treatment approaches for patients with TP53-mutated mantle cell lymphoma	15
Between rules and reality	15
Long-term data from the REACH study testing hydroxyurea to treat sickle cell anaemia in children in sub-Saharan Africa	15
Long term strategies for individuals with sickle cell disease	15
Public health and programme development in sickle cell disease in Ghana: the legacy of Kwaku Ohene-Frempong	14
Concerns on perioperative anaemia management in the FIT trial	14
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	14
Is dose-adjusted EPOCH-R the new standard for high-risk Burkitt lymphoma?	14
Oncology service priorities for the new UK Government	14
Should patients with Ph-negative acute lymphoblastic leukaemia who reach minimal residual disease negativity have HSCT?	14
Inequalities in the career pathway for paediatric HSCT and cellular therapy physicians	13
Virginia Abello Polo—a once-in-a-lifetime opportunity	13
Renal colocalisation of Rosai-Dorfman-Destombes disease and secondary AA amyloidosis successfully treated with lenalidomide and dexamethasone	13
Isolated IgG4-related disease of the left maxillary antrum	13
CAR T-cell therapies in China: rapid evolution and a bright future	13
Correction to Lancet Haematol 2025; 12: e128–37	12
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study	12
Correction to Lancet Haematol 2025; 12: e808–22	12
Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial	12
Iberdomide plus low-dose cyclophosphamide and dexamethasone in patients with relapsed and refractory multiple myeloma (the ICON study): a multicentre, single-arm, phase 2 trial	12
Correction to Lancet Haematol 2023; 10: e713–34	12
The value of anti-CD30 CAR T cells in Hodgkin lymphoma	12
Fitusiran prophylaxis in severe haemophilia without inhibitors	11
Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial	11
Mental health and psychological resilience in sickle cell disease	11
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomise	10
Environmental impact of haematology care—measurement and mitigation	10
Haematopoietic stem-cell transplantation for sickle cell disease in low-income and middle-income countries: the experience in India	10
Predictors of clinically relevant bleeding during extended anticoagulation for cancer-associated venous thromboembolism (API-CAT): a post-hoc analysis of a randomised, non-inferiority trial	10
CAR T-cell therapy: navigating real-world challenges beyond clinical trials	10
Overcoming the unmet need of Richter transformation: the use of pirtobrutinib	10
Expanding access to menstrual health: areas for attention	10
Cristóbal Frutos: confronting treatment barriers	10
Adverse event grading: the case of Duffy null-associated neutrophil counts	9
Lessons from both sides of the bedrail	9
Correction to Lancet Haematol 2024; 11: e510–20	9
Correction to Lancet Haematol 2025; 12: e978–85	9
Expecting more: the case for incorporating fertility services into comprehensive sickle cell disease care	9
Correction to Lancet Haematol 2024; 11: e38–50	9
Prioritising health equity alongside donation safety	9